345 completed, 184 unknown, 173 recruiting, 132 terminated. 449 Phase 2, 274 Phase 1, 118 Not applicable, 71 Phase 3, 12 Early Phase 1.
Follow Non Small Cell Lung Cancer: new trials by email Literature Review of Non Small Cell Lung Cancer trials Research Report on Non Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) Zanidatamab, Zongertinib - Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 24 | 2027-04-01 | 2026-10-28 |
| Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity | Phase 2 | Recruiting | Indiana University | 10 | 2027-01-01 | 2026-11-10 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer SBRT in stage III NSCLC - Non Small Cell Lung Cancer | Not applicable | Not yet recruiting | All India Institute of Medical Sciences | 20 | 2026-12-19 | 2026-09-24 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 89 | 2026-12-01 | 2026-02-02 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-22 | 2026-11-17 |
| Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers sample collection - Non Small Cell Lung Cancer, Melanoma (Skin Cancer) | Not applicable | Not yet recruiting | European Institute of Oncology | 360 | 2026-11-11 | 2026-11-04 |
| Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer TUB-040 - NSCLC, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Gilead Sciences | 80 | 2026-11-01 | 2026-09-16 |
| SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer SSGJ-706, SPGL008, Chemotherapy - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 220 | 2026-11-01 | 2026-10-15 |
| RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer Cemiplimab 350 mg IV - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2026-11-01 | 2026-10-05 |
| Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC Zipalertinib - EGFR, Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Stanford University | 42 | 2026-11-01 | 2026-09-03 |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 158 | 2026-11-01 | 2026-06-04 |
| ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer Physical activity recommendations, Physical Activity (PA) Intervention - Lung Neoplasms, Non Small Cell Lung Cancer | Not applicable | Recruiting | Centre Leon Berard | 40 | 2026-10-29 | 2026-11-03 |
| Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer Non Small Cell Lung Cancer | Not yet recruiting | Fox Chase Cancer Center | 200 | 2026-10-06 | 2026-10-02 | |
| Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer NovoTTF-200T System - NSCLC, Non Small Cell Lung Cancer | Not applicable | Withdrawn | University of Texas Southwestern Medical Center | 2026-10-01 | 2026-10-23 | |
| SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC Stereotactic Radiation Therapy, Envafolimab, Endostar - Non Small Cell Lung Cancer, Lung Neoplasms | Phase 2 | Not yet recruiting | The First People's Hospital of Lianyungang | 61 | 2026-10-01 | 2026-09-14 |
| OPTIMISE Lung SABR Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment, Investigational three fraction image-guided Stereotactic Ablative Radiotherapy (IG-SABR) - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Cancer Trials Ireland | 208 | 2026-10-01 | 2026-10-16 |
| Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC Tislelizumab, Fecal Microbiota Transplant(FMT) - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Se-Hoon Lee | 15 | 2026-09-30 | 2026-08-11 |
Showing 20 of 1034. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (1034) · Lung Neoplasms (164) · Melanoma (77) · Neoplasms (69) · Colorectal Neoplasms (65) · Ovarian Neoplasms (49) · Pancreatic Neoplasms (49) · Breast Neoplasms (48) · Squamous Cell Carcinoma of Head and Neck (48) · Neoplasm Metastasis (47) · Triple Negative Breast Neoplasms (43) · Carcinoma, Renal Cell (42) · Small Cell Lung Carcinoma (39) · Stomach Neoplasms (34) · Uterine Cervical Neoplasms (32)
Neoplasms by Site (1033) · Respiratory Tract Diseases (1033) · Bronchial Neoplasms (1032) · Carcinoma, Bronchogenic (1031) · Lung Diseases (1031) · Respiratory Tract Neoplasms (1031) · Thoracic Neoplasms (1031) · Neoplasms (965) · Lung Neoplasms (870) · Neoplasms by Histologic Type (166) · Skin Diseases (137) · Skin and Connective Tissue Diseases (137) · Neoplasms, Glandular and Epithelial (132) · Digestive System Diseases (117) · Digestive System Neoplasms (115)
Pemetrexed (101) · Carboplatin (92) · pembrolizumab (77) · Cisplatin (63) · Docetaxel (55) · Paclitaxel (50) · Nivolumab (44) · Gemcitabine (36) · Drug Therapy (30) · Erlotinib Hydrochloride (28) · osimertinib (28) · Bevacizumab (27) · Radiosurgery (24) · atezolizumab (22) · Ipilimumab (20)
Eli Lilly and Company (27) · AstraZeneca (23) · Hunan Province Tumor Hospital (16) · Hellenic Oncology Research Group (13) · Memorial Sloan Kettering Cancer Center (13) · Sun Yat-sen University (13) · Tianjin Medical University Cancer Institute and Hospital (12) · Duke University (9) · National University Hospital, Singapore (8) · Shanghai Pulmonary Hospital, Shanghai, China (8) · University Health Network, Toronto (8) · Yonsei University (8) · Fundación GECP (7) · Intergroupe Francophone de Cancerologie Thoracique (7) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (7)
United States (378) · China (226) · France (119) · Spain (94) · Italy (83) · Canada (73) · South Korea (73) · Australia (52) · United Kingdom (51) · Germany (45) · Netherlands (44) · Taiwan (44) · Belgium (43) · Greece (33) · Poland (25)
Mariano Provencio, MD (7) · Vassilis Georgoulias, MD (7) · Yongchang Zhang, MD (5) · Armando Santoro, MD (3) · Daniel Morgensztern, M.D. (3) · Dirk De Ruysscher, MD, PhD (3) · Francesco Grossi, MD (3)
PMID 23578144, PMID 25175099, PMID 25881079, PMID 26291023, PMID 30171779, PMID 33166722, PMID 35048355, PMID 36053283, PMID 40179330, PMID 42279342, PMID 11180735, PMID 11282431, PMID 11452123, PMID 11597807, PMID 11740992, PMID 12237924, PMID 12683544, PMID 12738306, PMID 12738307, PMID 12750523, PMID 12826306, PMID 1324899, PMID 14596509, PMID 14605072, PMID 15302749, PMID 15378503, PMID 15383520, PMID 15949587, PMID 16115740, PMID 16169670, PMID 16236914, PMID 16391372, PMID 16757720, PMID 16765528, PMID 17167516, PMID 17229875, PMID 17488518, PMID 17925563, PMID 18305939, PMID 18565793, PMID 18581114, PMID 18683299, PMID 18725106, PMID 19251380, PMID 19403881, PMID 19427740, PMID 19556022, PMID 19801201, PMID 20233825, PMID 20923544
2018 (8), 2023 (7), 2014 (6), 2017 (6), 2009 (5), 2016 (4), 2015 (3), 2019 (3), 2025 (3), P30CA012197 (3), 2004 (2), 2005 (1), 2008 (1), R01CA211705 (1), R01CA258681 (1)